Adjuvant Treatment of Colon Cancer
Author Information
Author(s): J Wils
Primary Institution: The Laurentius Hospital, Roermond, The Netherlands
Hypothesis
Can raltitrexed provide a better alternative to the standard Mayo regimen for adjuvant treatment of Dukes' C colon cancer?
Conclusion
Raltitrexed may offer similar efficacy to standard treatments with fewer side effects and a more convenient administration schedule.
Supporting Evidence
- Raltitrexed has shown similar response rates to standard therapy with 5-FU plus LV.
- Raltitrexed has a better tolerability profile compared to 5-FU plus LV.
- The Mayo regimen of 5-FU with low-dose LV is currently the standard treatment for Dukes' C colon cancer.
Takeaway
This study is about finding better ways to treat colon cancer after surgery, using a new drug called raltitrexed that might be easier for patients to take.
Methodology
Two large European trials (PETACC-1 and PETACC-2) were set up to compare raltitrexed with the Mayo regimen and various infusional 5-FU regimens.
Limitations
The study relies on data from ongoing trials and may not yet have conclusive results.
Participant Demographics
Patients with histologically confirmed Dukes' C adenocarcinoma of the colon.
Statistical Information
P-Value
P < 0.0001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website